SCHEMBL30348779

SCHEMBL30348779

FC(F)(F)O[C@H]1CC[C@@H](Nc2ncc3c(-c4ccc5ncccc5c4)c[nH]c3n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 6/20 0.49
▸ CLK2 P49760 3/20 0.49
▸ CLK3 P49761 2/20 0.49
▸ RET P07949 4/20 0.42
▸ ULK1 O75385 1/20 0.42
▸ ULK2 Q8IYT8 1/20 0.42
▸ CLK1 P49759 1/20 0.41
▸ CLK4 Q9HAZ1 1/20 0.41
▸ DYRK1B Q9Y463 1/20 0.40
▸ EIF2AK4 Q9P2K8 1/20 0.40
▸ CCNK O75909 4/20 0.39
▸ CDK12 Q9NYV4 4/20 0.39
▸ CDK7 P50613 3/20 0.39
▸ CCNH P51946 2/20 0.39
▸ MNAT1 P51948 2/20 0.39
▸ CCNT1 O60563 2/20 0.39
▸ CCNE1 P24864 2/20 0.39
▸ CDK2 P24941 2/20 0.39
▸ CDK9 P50750 2/20 0.39
▸ CDC7 O00311 5/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25520274 1.00 DYRK1A (0.49) DYRK1ACLK2CLK3RETULK1
SCHEMBL25520279 0.90 ULK1 (0.40) DYRK1ACLK2CLK3RETULK1
SCHEMBL30348299 0.90 ULK1 (0.40) DYRK1ACLK2CLK3RETULK1
SCHEMBL25519866 0.88 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25523274 0.88 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL30349409 0.88 RET (0.55) DYRK1ACLK2CLK3RETCLK1
SCHEMBL25265742 0.88 TDO2 (0.47) DYRK1ACLK2CLK3RETCLK4
SCHEMBL25200864 0.88 TDO2 (0.47) DYRK1ACLK2CLK3RETCLK4
SCHEMBL30406803 0.88 TDO2 (0.47) DYRK1ACLK2CLK3RETCLK4
SCHEMBL30348908 0.87 DYRK1A (0.51) DYRK1ACLK2CLK3RETCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 DYRK1A 1/4885CLK2 466/4885CLK3 1147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback